Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
- PMID: 27012953
- PMCID: PMC5543671
- DOI: 10.2174/1570159X14666160325121145
Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
Abstract
Background: Alzheimer's disease (AD) is the most common form of old age dementia. The formation of amyloid plaques (Aβ), neurofibrillary tangles and loss of basal forebrain cholinergic neurons are the hallmark events in the pathology of AD.
Literature review: Cholinergic system is one of the most important neurotransmitter system involved in learning and memory which preferentially degenerates in the initial stages of AD. Activation of cholinergic receptors (muscarinic and nicotinic) activates multiple pathways which result in post translational modifications (PTMs) in multiple proteins which bring changes in nervous system. Cholinergic receptors-mediated PTMs "in-part" substantially affect the biosynthesis, proteolysis, degradation and expression of many proteins and in particular, amyloid precursor protein (APP). APP is subjected to several PTMs (proteolytic processing, glycosylation, sulfation, and phosphorylation) during its course of processing, resulting in Aβ deposition, leading to AD. Aβ also alters the PTMs of tau which is a microtubule associated protein. Therefore, post-translationally modified tau and Aβ collectively aggravate the neuronal loss that leads to cholinergic hypofunction.
Conclusion: Despite the accumulating evidences, the interaction between cholinergic neurotransmission and the physiological significance of PTM events remain speculative and still needs further exploration. This review focuses on the role of cholinergic system and discusses the significance of PTMs in pathological progression of AD and highlights some important future directions.
Keywords: Acetylcholine; Alzheimer's disease; muscarinic receptors; nicotinic receptors; post translational modifications.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Figures
References
-
- Jucker M., Walker L.C. Neurodegeneration: Amyloid-β pathology induced in humans. Nature. 2015;525(7568):193–194. [http://dx. doi.org/10.1038/525193a]. [PMID: 26354478]. - PMC - PubMed
-
- Selkoe D.J., Schenk D. Alzheimers disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003;43:545–584. [http://dx.doi.org/10.1146/annurev.pharmtox.43.100901.140248]. [PMID: 12415125]. - PubMed
-
- Zilka N., Novak M. The tangled story of Alois Alzheimer. Bratisl. Lek Listy (Tlacene Vyd) 2006;107(9-10):343–345. [PMID: 17262985]. - PubMed
-
- Fu W., Jhamandas J.H. β-amyloid peptide activates non-α7 nicotinic acetylcholine receptors in rat basal forebrain neurons. J. Neurophysiol. 2003;90(5):3130–3136. [http://dx.doi.org/10.1152/ jn.00616.2003]. [PMID: 12890800]. - PubMed
-
- Glenner G., Wong C. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Alzheimer Dis. Assoc. Disord. 1988;2(2):134. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous